

EXTENDED REPORT

The sympathetic nervous system stimulates anti-inflammatory B cells in collagen-type II-induced arthritis

Georg Pongratz, Madlen Melzer, Rainer H Straub

Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany

Correspondence to

Georg Pongratz, Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine I, University Hospital Regensburg, 93042 Regensburg, Germany; georg.pongratz@klinik.uni-regensburg.de

Received 23 February 2011
Accepted 14 August 2011
Published Online First
27 September 2011

ABSTRACT

Background As previously shown, the sympathetic nervous system (SNS) shows proinflammatory activity during initiation of arthritis but is anti-inflammatory in established collagen-induced arthritis (CIA). Interleukin 10 (IL-10)-producing B cells suppress arthritis and are a potential target of the SNS because (1) B cells express functional β_2 -adrenoceptors (β_2 ARs) and (2) IL-10, at least in monocytes/macrophages, is regulated in a cAMP/PKA/CREB-dependent manner.

Objective To test the hypothesis that anti-inflammatory effects of the SNS in CIA are mediated by stimulating IL-10-producing anti-inflammatory B cells.

Methods Collagen-induced arthritis in DBA/1 mice, sympathectomy, adoptive B cell transfer, in vitro B cell culture, and assessment of B cell IL-10 production.

Results and conclusion Mice treated with B cells from SNS-intact mice showed less severe arthritis than mice treated with B cells from sympathectomised mice. This anti-inflammatory action of B cells from SNS-intact mice correlated with increased IL-10 produced by B cells, which was mediated by norepinephrine (NE), in a β_2 AR, PKA-dependent manner. However, an NE-mediated increase in IL-10 was seen only in B cells from immunised but not naive mice, explaining in part the anti-inflammatory properties of the SNS in the late phase of arthritis. Finally, animals treated with B cells isolated from immunised mice and activated in vitro in the presence of a β_2 AR stimulus showed a decrease in arthritis severity in comparison with controls, an approach that might be used for future cellular treatment strategies.

INTRODUCTION

The depletion of CD20+ B cells as a treatment option for some rheumatic disorders—for example, rheumatoid arthritis, has raised again the proposition that B cells have a pathogenetic role in these disorders. However, depletion of all CD20+ cells is an unspecific approach and risks the occurrence of serious side effects such as infection. The optimal treatment for B cells would be specific depletion of autoreactive B cells, on the one hand, and promotion of anti-inflammatory B cells, on the other. The mechanisms by which anti-inflammatory B cells suppress chronic inflammation in arthritis are not completely understood. However, one hallmark of anti-arthritic regulatory B cells is their ability to produce interleukin 10 (IL-10).¹

IL-10 is an anti-inflammatory cytokine, which suppresses antigen presentation by antigen-presenting cells, downregulates major histocompatibility

complex II molecules and inhibits the expression of co-stimulatory molecules, preventing sufficient co-stimulation of antigen-specific T cells. Additionally, IL-10 directly suppresses the production of proinflammatory cytokines, chemokines and matrix metalloproteinases in macrophages (reviewed by Mosser and Zhang²), which explains its anti-inflammatory potential in arthritis. The overall effect of IL-10 on the whole B-cell population is stimulatory rather than immunosuppressive because IL-10 leads to prolonged survival, augments co-stimulation and induces class switch recombination.² Nevertheless, a subpopulation of IL-10-producing B cells, so called CD1d^{high} CD5^{high} B10 cells,³ clearly shows anti-inflammatory properties in arthritis.^{1,4}

The human and murine promoter of the IL-10 gene contains several CREB-responsive elements.^{5,6} Thus, it is not surprising that IL-10 production can be regulated through PKA/CREB-dependent mechanisms, which have been shown in THP-1 cells and macrophages.^{5,7} Activity of PKA is increased by cAMP, which is generated, following the stimulation of Gs protein coupled receptors, such as the β_2 -adrenoceptor (β_2 AR); a functional β_2 AR has also been shown to be expressed on B cells.^{8,9} Additionally, we reported in collagen type II-induced arthritis (CIA) that the sympathetic nervous system (SNS) with its main neurotransmitter norepinephrine (NE) has a role in regulating IL-10 in arthritis and has a profound effect on arthritis severity.¹⁰ Furthermore, it has been shown that the SNS plays a proinflammatory role in the early phase and an anti-inflammatory role in the late phase of the disease.^{10,11} The proinflammatory effect of the SNS in the early phase of the disease can be mediated via increasing proinflammatory cytokines, such as interferon γ produced by T cells.¹² Additionally, it has been reported that FOXP3-negative CD4+CD25+ T cells also contribute to the proinflammatory effect of the SNS in the early phase of CIA.¹¹ However, the anti-inflammatory action of the SNS in the late phase of CIA has not yet been elucidated.

In this study, we tested the hypothesis that anti-inflammatory effects of the SNS in CIA are mediated by stimulating IL-10 producing anti-inflammatory B cells.

MATERIAL AND METHODS

Animals, induction of arthritis and arthritis scoring

Male DBA/1 mice 6–8 weeks old (Elevage Janvier, Le Genest St Isle, France) were housed in cages and

fed standard laboratory chow and water ad libitum. There was a 12 h light—dark cycle. Experiments were conducted according to institutional and governmental regulations for animal use (Government of the Oberpfalz AZ 54–2531.1-24/06).

Experimental arthritis was induced in DBA/1 mice, as previously described.¹⁰ On day 0, mice were immunised intradermally at the base of the tail with 100 µg of bovine type II collagen (CII; Chondrex, Redmond, Washington, USA) emulsified in an equal volume of complete Freund's adjuvant (CFA; Sigma-Aldrich Chemie, München, Germany). A booster immunisation (100 µg CII in CFA) was administered on day 21 as indicated. Clinical scoring points were assigned to each limb to assess arthritis as described previously.¹³ A score of 0 (no swelling), 1 (light swelling) or 2 (strong swelling) was determined for four toes at each paw, four paws and ankle/wrist joints. The maximum score for each mouse was 48 points. Arthritis scoring was performed in a blinded manner, by the same technical assistant, always at the same time of the day (11:00–12:00).

Adoptive transfer experiments

Three groups of mice were immunised as described above (control donor mice, sympathectomised donor mice and sympathectomised recipient mice, figure 1A). On day 28, donor mice were killed by cervical dislocation, spleens were removed and immediately put into ice-cold phosphate-buffered saline (PBS). Splenectomy was performed in recipient mice at day 28 to remove the majority of the intrinsic B-cell pool. After preparing single-cell suspensions of donor splenocytes, B cells were isolated by magnetic bead cell sorting using mouse anti-B220 magnetic beads (MACS MicroBeads; Miltenyi Biotec, Bergisch Gladbach, Germany). After isolation, >95% of the cells were CD19+/CD20+ B cells as assessed by fluorescence activated cell sorter (FACS) analysis. Donor B cells (5×10⁶/200 µl PBS) were then injected into the tail vein of recipient mice (day 28 post-immunisation (p.i.)). One group received 200 µl PBS as treatment control (figure 1A). After transfer, clinical scores were obtained every 2–3 days until the end of experiment (day 63). After sacrificing the mice, heart blood was obtained and anti-CII antibody titres were determined in serum using a commercially available ELISA kit (MD Biosciences GmbH, Zürich, Switzerland).

Culture of splenocytes and B cells

Spleens were removed between 11:00 and 12:00. Single-cell suspensions were obtained by passing spleens through a nylon mesh. For splenocyte cultures, 5×10⁵ cells/200 µl were cultured in complete RPMI medium (cRPMI: RPMI 1640, 25 mM HEPES, pH 7.4, 5% fetal calf serum, 30 µM mercaptoethanol, 0.57 mM ascorbic acid, 100 U/ml penicillin, 100 µg/ml streptomycin (all from Sigma, Munich, Germany)) in 96-well plates and stimulated with anti-CD40 (clone: FGK 45.5, Miltenyi Biotec, Bergisch Gladbach, Germany, 5 µg/ml) and bovine CII (Chondrex, Redmond, Washington, USA, 50 µg/ml) in the presence or absence of NE (10^{−6} M, Sigma) for 4–5 days. For B-cell cultures, cells were isolated using magnetic bead cell sorting by depleting CD43⁺, CD4⁺ and Ter119⁺ cells from whole splenocyte suspensions (B-cell isolation kit, Miltenyi Biotec, Germany). After isolation, >96% of the cells were CD19/CD20 positive B cells. Cells were resuspended in cRPMI containing anti-CD40 (5 µg/ml, clone: FGK 45.5, Miltenyi Biotec, Bergisch Gladbach, Germany) and functional grade IL-4 (1 ng/ml, eBioscience, Frankfurt, Germany) and cultured at a density of 2×10⁶ cells/ml in 24-well plates for 4–5 days in the presence or absence of NE, the β₂AR specific agonist terbutaline, the protein kinase A (PKA) inhibitor H89, or the specific β₂AR antagonist

nadolol at indicated concentrations. For experiments using H89 or nadolol, cells were incubated for 30 min before adding NE or terbutaline, respectively.

Treatment of mice with early arthritis with cultured B cells

Splenic B cells were obtained from immunised mice at day 21 after immunisation and resuspended in cRPMI containing anti-CD40/IL-4 as described above. B cells were cultured for 5 days in 12-well plates at of 2×10⁶/ml in the presence or absence of NE, or terbutaline, or terbutaline + nadolol as indicated. After 5 days, cells were counted, washed five times and resuspended in PBS at 2×10⁶ live B cells/100 µl. Immunised mice beginning to show signs of synovitis at day 18 were treated with 2×10⁶ B cells intravenously and the arthritis score was recorded thereafter.

Restimulation and assessment of IL-10 production

Restimulation of cultured cells and assessment of intracellular IL-10 was performed in accordance with methods published elsewhere.^{1,3} Briefly, after 4–5 days of culture cells were stimulated with phorbol myristate acetate (PMA; 50 ng/ml; Sigma), ionomycin (500 ng/ml; Sigma) and *lipopolysaccharides* (LPS, 10 µg/ml), as indicated. For IL-10 protein detection, cell-free supernatant was analysed using a BD OptEIA mouse IL-10 ELISA kit (BD Bioscience, Heidelberg, Germany). For intracellular FACS analysis, brefeldin A (10 µg/ml; Sigma) was added together with PMA and ionomycin. Cells were stained with fluorescein isothiocyanate-anti-mouse CD19 (clone: MB 19-1, eBioscience) for 15 min on ice. Then cells were fixed (2% paraformaldehyde, 20 min at 4°C), permeabilised using Cytofix/Cytoperm (BD-Pharmingen, Heidelberg, Germany) and stained with phycoerythrin-IL-10 monoclonal antibody (clone: JES5-16E3; eBioscience) or respective isotype control for 25 min on ice. FACS analysis was performed on a FACS Calibur (Becton Dickinson Immunocytometry Systems, San Jose, California, USA). Data were analysed with FlowJo Software (V.7.2.4.; Tree Star Inc, Ashland, Oregon, USA) or WinMDI2.8 (<http://facs.scripps.edu/software.html>), respectively.

Sympathectomy

Sympathectomy was performed using saporin-coupled anti-dopamine-β-hydroxylase antibodies or saporin-coupled control antibodies (Advanced Targeting Systems, San Diego, California, USA)^{10,11} by intraperitoneal injection (5 µg per animal in PBS) 7 days before immunisation. The NE content in the spleen was reduced by 78% at the time of immunisation, demonstrating the efficacy of sympathectomy.

Statistical analysis

The non-parametric Mann–Whitney test was used to compare two groups and analysis of variance with post hoc tests was used to compare multiple groups. All analyses were conducted using Sigma Plot for Windows (version 11; Systat software Inc.). p Values <0.05 were considered significant.

RESULTS

The SNS ameliorates CIA by promoting anti-inflammatory B cells in vivo

To test the hypothesis that the SNS promotes the development of anti-inflammatory B cells in CIA, B cells were adoptively transferred as described above and as shown in figure 1A. In arthritic mice treated with B cells from SNS-intact mice arthritis




Figure 1 B cells obtained from sympathetic nervous system (SNS)-intact mice show regulatory potential in collagen type II-induced arthritis. (A) Experimental design: DBA1/J mice were depleted of the sympathetic nervous system by saproin (SAP)-conjugated anti-dopamine β -hydroxylase antibodies (depleted sympathetic nervous system (SNS⁻)), or treated with SAP-conjugated isotype control antibodies (SNS⁺) 7 days before immunisation with bovine collagen type II in complete Freund's adjuvant. On day 28, splenectomy was performed, B cells were isolated and SNS⁻ arthritic mice were treated with B cells from either SNS⁻ or SNS⁺ donors, respectively. One group was treated with phosphate-buffered saline (PBS) only. (B) Transfer of SNS⁺ B cells stops progression of collagen-induced arthritis. Arthritis score was determined by a blinded observer during the indicated time period post-immunisation (days p.i.). A general linear statistical model (two-way analysis of variance with Holm-Sidak post hoc analysis) showed between-group differences for mice treated with SNS⁺ B cells versus mice treated with PBS ($p=0.008$) and mice treated with SNS⁻ B cells ($p<0.001$), respectively. No significant group difference was found between mice treated with PBS and mice treated with SNS⁻ B cells ($p=0.09$). The average score of two independent experiments (% Ctrl) is shown. n = total number of mice. Error bars represent the SEM. (C) Serum level of anti-collagen type II antibodies (anti-CII) at the last day of the experiment as determined by ELISA.

progression stopped about 14 days after treatment (figure 1B), whereas treatment with B cells obtained from SNS-depleted animals resulted in a short-term aggravation of the disease as compared with the PBS-treated control group (figure 1B). This result supports the hypothesis that the SNS promotes development of B cells that show anti-inflammatory properties in the CIA mouse model. The effect was not mediated by a change in anti-CII antibody titres at day 63. FACS analysis also showed that

the percentage of B cells in the spleen and in peripheral blood was not influenced by sympathectomy (data not shown).

The SNS increases IL-10 produced by B cells in vivo

B cells producing IL-10 have an anti-inflammatory action in CIA, and the regulatory regions of the IL-10 gene contain cAMP-responsive elements,¹⁶ rendering IL-10-producing B cells a possible target for the SNS. To determine if the SNS changes the




Figure 2 Interleukin (IL)-10 produced by splenic B cells is increased via the sympathetic nervous system in vivo following immunisation. (A) Experimental design. DBA/1J mice were treated with saporin-coupled anti- β hydroxylase antibodies (n=6) or saporin-coupled isotype control antibodies (n=6) 7 days before immunisation with bovine collagen type II in complete Freund's adjuvant (CFA, day 0). (B) At day 19, 5×10^6 splenic B cells were stimulated with phorbol myristate acetate (50 ng/ml) and ionomycin (500 ng/ml) for 20 h and IL-10 was determined in cell-free supernatants by ELISA. p Value was determined by Mann-Whitney test. Results are presented as box plots, horizontal lines represent the median value. SNS, sympathetic nervous system.

ability of B cells to produce IL-10 in vivo, splenic B cells obtained from immunised and non-immunised mice at day 19 p.i. from SNS-depleted and SNS-intact mice were compared (figure 2A). B cells obtained from SNS-depleted mice produced significantly less IL-10 than the same number of B cells from SNS-intact mice

(figure 2B). When B cells were isolated from non-immunised animals sympathectomy did not influence the amount of IL-10 produced (data not shown). These results suggest that one function of the SNS in vivo is to promote IL-10-producing B cells during activation after immunisation with CII and CFA.

Norepinephrine differentially regulates IL-10 produced by B cells from naive or antigen-experienced spleens

Owing to earlier findings that the SNS shows proinflammatory properties during the early phase and anti-inflammatory properties during the late phases of CIA,¹⁰ it was determined if NE, the main SNS neurotransmitter, differentially regulates IL-10 produced by cultured naive splenocytes as compared with splenocytes obtained from antigen-experienced mice. Antigen-experienced splenocytes cultured for 4–5 days in the presence of anti-CD40, CII and NE showed increased IL-10 production after restimulation with PMA, ionomycin and LPS, as compared with cells in the absence of NE (figure 3A). FACS analysis showed that an increase in intracellular IL-10 in lymphocytes was mainly seen in CD19+ B cells (figure 3B). However, this NE-induced increase in IL-10 was not seen when naive-splenocytes were used in a similar experiment (figure 3C), indicating that immunisation before stimulation with NE renders some IL-10-producing, antigen-experienced splenocytes—for example, B cells, responsive to this neurotransmitter.

Norepinephrine acts directly on B cells to increase IL-10 production

To determine whether the increase in IL-10-producing B cells, after activation of splenocytes in the presence of NE is dependent on cells other than B cells in the culture, we isolated B cells from naive and antigen-experienced spleens and activated them with anti-CD40 and IL-4 in the absence (Ctrl) or presence of NE for 5 days and analysed IL-10+/CD19+ cells by FACS (figure 4A). The results are expressed as a percentage of control (% Ctrl, anti-CD40/IL-4 only). The absolute values for the percentage of IL-10+/CD19+ B cells from naive mice ($3.1\% \times 1.2$) and antigen-experienced mice ($2.6\% \times 1.3$) were not significantly different (p=0.953). As shown in figure 4A, NE in a concentration-dependent manner increases IL-10+/CD19+ B cells when isolated from spleens of mice immunised with CII/CFA (day p.i. 35–65). The increase was significant at concentrations of 10^{-8} to 10^{-6} mol/l (figure 4A, solid circles). However, when B cells from naive mice were used, the population of IL-10+ B cells did not change in the presence of NE (figure 4A, open circles). These results show that NE directly acts on B cells to increase IL-10+ cells, but only when the cells were taken from antigen-experienced spleens.

Norepinephrine increases IL-10 produced by B cells in a β_2 AR/PKA-dependent manner

Since it is known that B cells express functional β_2 AR, we next determined if specific stimulation of this receptor with terbutaline could mimic the effect of NE. Terbutaline increased IL-10 protein produced by B cells (isolated at day 35–40 p.i.) in a concentration-dependent manner (figure 4B). Additionally, the use of a specific PKA inhibitor, H89, showed that the terbutaline-induced increase in IL-10 was mediated through a PKA-dependent pathway (figure 4C). The addition of H89 prevented the increase of IL-10, and also reversed the terbutaline effect, resulting in decreased IL-10 production. This result suggests a second signalling pathway downstream of the β_2 AR, which leads to a decrease in IL-10 production upon stimulation of the receptor. Taken together, these results suggest that the increase




Figure 3 Norepinephrine differentially regulates interleukin (IL)-10 produced by antigen experienced or naïve splenocytes, respectively. Splenocytes from mice immunised with collagen type II and complete Freund's adjuvant (A, >day 60 post-immunisation) or naïve spleen cells from DBA1/J mice (C) were activated with anti-CD40 and bovine collagen type II in the presence (+NE) or absence (-NE) of norepinephrine (10^{-6} M). After 4–5 days, cells were washed and stimulated with phorbol myristate acetate, ionomycin and lipopolysaccharide, and IL-10 protein concentration was determined by ELISA at indicated time points. *** $p < 0.001$ was determined by Mann–Whitney U test. n.s., not significant. Results of four independent experiments with four replicates each are shown. (B) Representative FACS analysis of stimulated splenocytes after culture in the absence (Ctrl) or presence (+NE) of norepinephrine 10^{-6} M. Analysis of expression of intracellular IL-10 and CD19 as indicated. The number in the rectangular region indicates the percentage of IL10+/CD19+ cells.

in IL-10 produced by anti-CD40/IL-4-activated B cells isolated from antigen-experienced spleens is mediated via the β_2 AR in a PKA-dependent manner.

Treatment of CIA with β_2 AR-stimulated B cells isolated from antigen-experienced mice ameliorates disease progression

To show that the increase in IL-10+ B cells after β_2 AR stimulation of B cells from antigen-experienced mice in vitro is of relevance in vivo, arthritic mice were treated with B cells activated

in the absence or presence of NE, terbutaline, or terbutaline + nadolol, respectively (figure 5A). Mice treated with anti-CD40/IL-4-activated B cells (B-cell control) or PBS, respectively, showed the expected increase of arthritis severity over time (figure 5B). There was a trend towards a faster increase of arthritis scores in the B-cell control group as compared with PBS control in the first 10 days after treatment ($p = 0.074$), but no overall significant difference ($p = 0.099$). On the other hand, mice receiving B cells activated in the presence of either terbutaline or NE showed significantly reduced arthritis severity as compared with controls




Figure 4 Norepinephrine increases interleukin (IL)-10-producing splenic B cells via stimulation of β_2 -adrenergic receptors in a concentration-dependent and protein kinase A-dependent manner. Splenic B cells from antigen-experienced mice (A, solid circles) and naïve mice (A, open circles) were cultured with anti-CD40 and IL-4 in the absence or presence of norepinephrine (A) or terbutaline (B) at indicated concentrations. (C) Terbutaline (Terb) was used at 10^{-6} M, H89 at $1 \mu\text{g/ml}$. After 4–5 days of culture, B cells were stimulated with phorbol myristate acetate, ionomycin and lipopolysaccharide in the presence (A) or absence (B, C) of brevidin A for 8–10 h. The percentage of IL10⁺/CD19⁺ B cells or IL-10 protein concentration was determined by FACS analysis (A) or ELISA (B, C), respectively. Mean values expressed as percentage of control (anti-CD40/IL-4 only, % Ctrl) of six independent experiments (A, closed circles) and eight independent experiments (A, open circles) are shown. (B, C) Mean values for three independent experiments (B) and two independent experiments (C) are shown. p Values were determined by analysis of variance with Holm–Sidak (A, C) and Bonferroni (B) post hoc tests, respectively. Error bars represent the SEM. *** $p<0.001$; ** $p<0.01$.

(figure 5). Additionally, mice treated with B cells activated in the presence of terbutaline and nadolol did not differ as compared with the control groups ($p=0.074$). Taken together the results

suggest that a β_2 AR stimulus during activation of B cells from antigen-experienced mice in vitro increases the anti-inflammatory activity of these cells in vivo, by increasing IL-10⁺ B cells.




Figure 5 Treatment of collagen-induced arthritis with B cells activated in vitro in the presence of a β_2 -adrenoceptor (β_2 AR) agonist ameliorates disease progression. (A) Experimental design: five mice were immunised with bovine collagen type II (CII) and complete Freund's adjuvant (CFA). At day 21 post immunisation (p.i.) naïve splenic B cells were isolated and activated for 5 days with anti-CD40/interleukin (IL)-4 in the presence or absence of norepinephrine (10^{-6} M), terbutaline (10^{-6} M), or terbutaline (10^{-6} M) + nadolol (10^{-5} M). B cells were then vigorously washed and resuspended in phosphate-buffered saline (PBS). Six mice with collagen-induced arthritis per group (anti-CD40/IL-4, + norepinephrine, + terbutaline, + terbutaline + nadolol) were injected intravenously with 2×10^6 B cells per mouse or with PBS only at day 18 p.i. (B) Transfer of β_2 AR-treated B cells significantly slowed arthritis progression. Arthritis score was determined by a blinded observer during the indicated time period post immunisation (days p.i.). A general linear statistical model (two-way analysis of variance with Student–Newman–Keuls post hoc analysis) showed between-group differences for mice treated with B cells activated in the presence of norepinephrine or terbutaline, respectively, as compared with mice treated with PBS, or B cells activated in the presence of nadolol + terbutaline ($p < 0.001$ for all comparisons). No significant group difference was found between mice treated with PBS and mice treated with B cells activated in the presence of nadolol + terbutaline or B cells activated with anti-CD40/IL-4 only. Symbols represent the group means, the error bars represent the SEM.

DISCUSSION

Recent studies using the CIA model system show, that the SNS has a dual role with respect to disease severity, with proinflammatory activity in the early phase and an anti-inflammatory

influence in the late phase of arthritis.^{10 11} Our results in this study suggest that the anti-inflammatory activity of the SNS in the late phase of arthritis is, at least in part, mediated by increasing the anti-inflammatory properties of B cells. We propose

that in the late phase of CIA a sympathetic stimulus increases the percentage of IL-10-producing, anti-inflammatory B cells, which can slow down arthritis progression.¹ Our results do not exclude the possibility that the SNS also influences other cells—for example, monocytes/macrophages, which have been shown to increase IL-10 production after stimulation of β_2 AR in the human system.^{5–7,14} However, transferring splenic B cells in vitro, activated in the presence of a β_2 AR stimulus, is sufficient to significantly slow arthritis progression, showing the important role of the SNS and B cells, respectively, in modulating disease severity in arthritis.

A necessary prerequisite for the SNS to increase IL-10-producing B cells was prior immunisation with CII and CFA, which underlines the importance of this mechanism after initiation of arthritis (late phase). The need for prior immunisation indicates that a proinflammatory milieu in the spleen is important to render naive B cells responsive for a β_2 AR-induced increase in IL-10. The reason for this is unclear. However, one possibility might be an increase in β_2 AR signalling capacity by decreasing G-protein-coupled receptor kinase (GRK)-2, which was reported to be decreased in peripheral blood mononuclear cells from patients with rheumatoid arthritis and upon antigen exposure in B and T cells in a rat model of adjuvant arthritis.^{15,16} This leads to the hypothesis that an immune challenge decreases GRK-2 in naive B cells, resulting in less β_2 AR phosphorylation, which slows internalisation and desensitisation of β_2 ARs. This results in increased and prolonged β_2 AR signalling, which might cross a certain threshold to initiate PKA-dependent IL-10 production in B cells.

The importance of IL-10 in modulating arthritis severity is underlined by several correlative studies showing a link between genetic variation at the IL-10 gene locus and severity of arthritis,^{17–18} but human studies treating arthritis with systemic IL-10 showed almost no effect (reviewed by Asadullah *et al*¹⁹). However, a small number of antigen-specific T cells transfected to produce IL-10 were capable of suppressing inflammation in proteoglycan-induced arthritis,²⁰ probably by cell–cell interaction at the site of inflammation without an increase in systemic IL-10. This fits together with our results, which show no change in IL-10 serum levels upon transfer of β_2 AR-stimulated B cells (data not shown). It was not in the scope of this study to delineate, whether local suppressive effects occur in the joints, the lymph nodes, or the spleen. However, in adoptive transfer experiments, recipient animals were splenectomised before transfer of B cells, which indicates that homing to the spleen is not necessary for the suppressive effect of B cells from SNS-intact animals.

As mentioned in the introduction, one problem with B-cell depleting strategies in rheumatic disease is the unselective approach, which depletes both, proinflammatory and anti-inflammatory B cells. In light of our results, it might be possible to enrich anti-arthritic B cells in vitro using β_2 -adrenergic stimuli. Combining this approach with B-cell depletion and retransfer of in vitro generated anti-arthritic B cells might open new therapeutic possibilities for the future.

Acknowledgements The authors thank Anja Sabo for excellent technical assistance.

Funding This study was funded by the institution and by the Deutsche Forschungsgemeinschaft (DFG FOR696, PO801/4-1).

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Contributors GP study design, data acquisition, statistical data analysis, data interpretation, manuscript preparation; MM study design, data acquisition; RHS study design, data interpretation, substantial manuscript revision.

REFERENCES

1. **Mauri C**, Gray D, Mushtaq N, *et al*. Prevention of arthritis by interleukin 10-producing B cells. *J Exp Med* 2003;**197**:489–501.
2. **Mosser DM**, Zhang X. Interleukin-10: new perspectives on an old cytokine. *Immunol Rev* 2008;**226**:205–18.
3. **Yanaba K**, Bouaziz JD, Haas KM, *et al*. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. *Immunity* 2008;**28**:639–50.
4. **Mauri C**, Ehrenstein MR. The 'short' history of regulatory B cells. *Trends Immunol* 2008;**29**:34–40.
5. **Platzer C**, Fritsch E, Elsner T, *et al*. Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells. *Eur J Immunol* 1999;**29**:3098–104.
6. **Platzer C**, Meisel C, Vogt K, *et al*. Up-regulation of monocytic IL-10 by tumor necrosis factor- α and cAMP elevating drugs. *Int Immunol* 1995;**7**:517–23.
7. **Brenner S**, Prösch S, Schenke-Layland K, *et al*. cAMP-induced Interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation. *J Biol Chem* 2003;**278**:5597–604.
8. **Podofil JR**, Sanders VM. CD86 and beta2-adrenergic receptor stimulation regulate B-cell activity cooperatively. *Trends Immunol* 2005;**26**:180–5.
9. **Pongratz G**, McAlees JW, Conrad DH, *et al*. The level of IgE produced by a B cell is regulated by norepinephrine in a p38 MAPK- and CD23-dependent manner. *J Immunol* 2006;**177**:2926–38.
10. **Härle P**, Möbius D, Carr DJ, *et al*. An opposing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the local lymph nodes and spleen of mice with type II collagen-induced arthritis. *Arthritis Rheum* 2005;**52**:1305–13.
11. **Härle P**, Pongratz G, Albrecht J, *et al*. An early sympathetic nervous system influence exacerbates collagen-induced arthritis via CD4+CD25+ cells. *Arthritis Rheum* 2008;**58**:2347–55.
12. **Straub RH**, Rauch L, Fassold A, *et al*. Neuronally released sympathetic neurotransmitters stimulate splenic interferon-gamma secretion from T cells in early type II collagen-induced arthritis. *Arthritis Rheum* 2008;**58**:3450–60.
13. **Fassold A**, Falk W, Anders S, *et al*. Soluble neuropilin-2, a nerve repellent receptor, is increased in rheumatoid arthritis synovium and aggravates sympathetic fiber repulsion and arthritis. *Arthritis Rheum* 2009;**60**:2892–901.
14. **Heo YJ**, Joo YB, Oh HJ, *et al*. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. *Immunol Lett* 2010;**127**:150–6.
15. **Lombardi MS**, Kavelaars A, Schedlowski M, *et al*. Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis. *FASEB J* 1999;**13**:715–25.
16. **Lombardi MS**, Kavelaars A, Cobelens PM, *et al*. Adjuvant arthritis induces down-regulation of G protein-coupled receptor kinases in the immune system. *J Immunol* 2001;**166**:1635–40.
17. **de PB**, Peri-Lopez M, Ballina-Garcia FJ, *et al*. Interleukin 10 and tumor necrosis factor- α genotypes in rheumatoid arthritis—association with clinical response to glucocorticoids. *J Rheumatol* 2010;**37**:503–11.
18. **Marinou I**, Healy J, Mewar D, *et al*. Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. *Arthritis Rheum* 2007;**56**:2549–56.
19. **Asadullah K**, Sterry W, Volk HD. Interleukin-10 therapy—review of a new approach. *Pharmacol Rev* 2003;**55**:241–69.
20. **Guichelaar T**, ten Brink CB, van Kooten PJ, *et al*. Autoantigen-specific IL-10-transduced T cells suppress chronic arthritis by promoting the endogenous regulatory IL-10 response. *J Immunol* 2008;**180**:1373–81.



The sympathetic nervous system stimulates anti-inflammatory B cells in collagen-type II-induced arthritis

Georg Pongratz, Madlen Melzer and Rainer H Straub

Ann Rheum Dis 2012 71: 432-439 originally published online September 27, 2011

doi: 10.1136/ard.2011.153056

Updated information and services can be found at:
<http://ard.bmj.com/content/71/3/432>

These include:

References

This article cites 19 articles, 7 of which you can access for free at:
<http://ard.bmj.com/content/71/3/432#BIBL>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Degenerative joint disease](#) (4641)
[Musculoskeletal syndromes](#) (4951)
[Biological agents](#) (545)
[Drugs: musculoskeletal and joint diseases](#) (700)
[Immunology \(including allergy\)](#) (5144)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>